论文部分内容阅读
目的:系统评价利培酮治疗Tourette综合征的疗效和安全性。方法:计算机检索PubMed、Cochrane对照试验中心数据库、CBM、CNKI、VIP,辅以手工检索相关文献的参考文献目录,全面收集利培酮治疗Tourette综合征的临床随机对照试验,由两名评价员单独筛选、提取资料并对其进行质量评价。结果:共纳入5个随机对照试验(共172名患者,年龄范围是6～65岁),两个安慰剂对照试验,三个有效对照试验,由于存在临床异质性,未进行Meta分析,仅进行描述性分析。和安慰剂相比,利培酮可以明显改善对抽动的控制,未出现严重不良反应;目前研究显示利培酮与哌迷清及可乐定对Tourette综合征抽动的控制无明显差异。结论:利培酮对Tourette综合征患者的抽动控制短期有效且耐受性良好,但远期疗效及不良反应有待大样本、长疗程进一步研究。
Objective: To systematically evaluate the efficacy and safety of risperidone in the treatment of Tourette’s syndrome. METHODS: PubMed, Cochrane Central Register of Controlled Trials, CBM, CNKI and VIP were searched by computer. A manual reference search of relevant literature was conducted. A randomized controlled clinical trial of risperidone in the treatment of Tourette’s syndrome was conducted. Two randomized controlled trials Screening, data extraction and quality evaluation. RESULTS: Five RCTs (172 patients in total, age range 6 to 65 years) were enrolled. Two placebo-controlled trials and three controlled trials were conducted because of clinical heterogeneity and no Meta-analysis, only Descriptive analysis. Compared with placebo, risperidone can significantly improve the control of tic, no serious adverse reactions; the current study shows that risperidone and piperdine and clonidine Tourette syndrome tic control no significant difference. Conclusion: Risperidone has short-term efficacy and good tolerance to tic-tacrolimus in patients with Tourette’s syndrome. However, long-term curative effects and adverse reactions require large sample and long course of treatment for further study.